UBS: Raise target price for LINK REIT (00823) to 47.2 Hong Kong dollars, market has not factored in asset recycling opportunities.
Although the short-term fundamentals remain weak, the bank expects to see upside potential from potential asset cycles and share buybacks.
UBS released a research report stating that the target price for LINK REIT (00823) has been raised from 42 Hong Kong dollars to 47.2 Hong Kong dollars to reflect potential asset recycling and share buyback plans, with a "buy" rating.
The report pointed out that Link will announce its performance for the fiscal year ending in March 2026 on May 28th, predicting a year-on-year decrease of 8% to 2.51 Hong Kong dollars in fund distribution per unit for the 2026 fiscal year, with a negative 8% rental adjustment rate for Hong Kong retail renewals, compared to the negative 7.5% in the first nine months of the fiscal year ending in December 2026. Although the short-term fundamentals remain weak, the bank sees upside potential from potential asset recycling and share buybacks.
The bank pointed out that after selling Thomson Plaza, office assets in Australia and the UK, as well as logistics assets in China, could be the next targets for sale by Link. Underperforming shopping malls in Guangzhou and Beijing could also be potential mid-term sale targets. Overall, non-core assets could reach 34 billion Hong Kong dollars, accounting for about 15% of the total assets. The current stock price still provides a dividend yield of over 6%, much higher than peers (HANG LUNG PPT / Nine Dragons / Xi Shen between 5.3% and 5.8%), and the market is believed to have not fully factored in its revaluation potential.
Related Articles

KUAISHOU-W(01024) clarifies rumors about the split of Coolin AI: Currently evaluating restructuring plan, final agreement has not been signed yet.

GALAXY ENT (00027) net profit for the first quarter was 12.4 billion Hong Kong dollars, up 11% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276) signs strategic cooperation and licensing agreement with Bristol-Myers Squibb.
KUAISHOU-W(01024) clarifies rumors about the split of Coolin AI: Currently evaluating restructuring plan, final agreement has not been signed yet.

GALAXY ENT (00027) net profit for the first quarter was 12.4 billion Hong Kong dollars, up 11% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276) signs strategic cooperation and licensing agreement with Bristol-Myers Squibb.

RECOMMEND

Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026

HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026

The Chip Stock Frenzy Is Still Accelerating
11/05/2026


